Prolong Pharmaceuticals
Manufacturing · New Jersey, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
300 Corporate Ct Ste B, South Plainfield...Phone Number
(908) 444-4660Website
www.prolongpharma.comRevenue
$35.2 MillionIndustry
About Prolong Pharmaceuticals
Prolong Pharmaceuticals is focused on developing PP-007, an investigational therapy designed to deliver oxygen to brain tissue during and after treatment for acute ischemic stroke. The company aims to improve recovery outcomes for stroke patients by addressing the issue of oxygen deprivation even after clot removal. Prolong's clinical trials, including the HEMERA-1 study, have shown promising results, with a higher percentage of patients living independently at 90 days when treated with PP-007 alongside standard care. The company is actively pursuing regulatory designations and further clinical trials to advance its innovative treatment.Explore more
Prolong Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Prolong Pharmaceuticals
Compare insights from companies similar to Prolong Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Prolong Pharmaceuticals Tech Stack
A closer look at the technologies used by Prolong Pharmaceuticals
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Prolong Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Prolong Pharmaceuticals is focused on developing PP-007, an investigational therapy designed to deliver oxygen to brain tissue during and after treatment for acute ischemic stroke. The company aims to improve recovery outcomes for stroke patients by addressing the issue of oxygen deprivation even after clot removal. Prolong's clinical trials, inclu... Read More
